Valneva: Austrian/french biotech company Valneva announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15. The overall Phase 2 objectives for VLA15 are to determine the optimal dosage level and vaccination schedule for use in Phase 3 pivotal field efficacy studies, based on immunogenicity and safety data. Following the Run-In phase for Valneva’s first Phase 2 study VLA15-201, the two lead dosage levels have been selected for further development based on Data and Safety Monitoring Boardclearance. The objective of the now initiated second Phase 2 study VLA15-202 is to evaluate an alternative immunization schedule for the two lead dosage levels. The Phase 2 duration is expected to be approximately two years with initial data (primary endpoint) expected mid-2020.
Valneva: weekly performance: 3.21%

OMV, Verbund: OMV, the international, integrated oil and gas company headquartered in Vienna, and Verbund, Austria's leading electricity company and one of the largest hydropower producers in Europe, have intensified their strategic cooperation for the future of energy and signed memoranda of understanding (MoU) to this effect. First joint project is to build Austria's largest photovoltaic plant. The power facility will have a PV capacity of 16 MWp, divided between the Schönkirchen site with around 9 MWp and Neusiedl an der Zaya accounting for around 7 MWp. The plant will cover an approx. 200,000 m² plot owned by OMV, whereby a total of around 60,000 PV modules should allow the solar park to deliver around 18 GWh of power. This represents the annual power consumption of about 5,500 households and will lead to savings of some 12,000 tonnes of CO2 per year. The plant is set to start operating in the fourth quarter of 2020. The companies further evaluate the option to build an electrolytic hydrogen production facility. This technology takes power from renewables and uses it to split water via electrolysis. The green hydrogen that is produced by this process can be used for chemical production processes. OMV is primarily researching the use of hydrogen to hydrogenate CO2, in order to reduce carbon emissions from industrial facilities.
OMV: weekly performance: 2.47%
Verbund: weekly performance: -0.83%